Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The IDH2 inhibitor enasidenib was recently approved for IDH2-mutated relapsed or refractory AML. We conducted a multi-center, phase I trial of maintenance enasidenib following alloge...

Descripción completa

Detalles Bibliográficos
Autores principales: Fathi, Amir T., Kim, Haesook T., Soiffer, Robert J., Levis, Mark J., Li, Shuli, Kim, Annette S., Mims, Alice S., DeFilipp, Zachariah, El-Jawahri, Areej, McAfee, Steven L., Brunner, Andrew M., Narayan, Rupa, Knight, Laura W., Kelley, Devon, Bottoms, AJ S., Perry, Lindsey H., Wahl, Jonathan L., Brock, Jennifer, Breton, Elayne, Ho, Vincent T., Chen, Yi-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649991/
https://www.ncbi.nlm.nih.gov/pubmed/36150050
http://dx.doi.org/10.1182/bloodadvances.2022008632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649991/
https://www.ncbi.nlm.nih.gov/pubmed/36150050
http://dx.doi.org/10.1182/bloodadvances.2022008632

Ejemplares similares